Trial Profile
A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2022
Price :
$35
*
At a glance
- Drugs Navtemadlin (Primary) ; Ruxolitinib
- Indications Polycythaemia vera
- Focus Therapeutic Use
- Sponsors Kartos Therapeutics
- 11 Mar 2022 This trial has been discontinued in Hungary according to European Clinical Trials Database record
- 10 Mar 2022 This trial has been discontinued in Bulgaria (Date of the global end of the trial : 11-Feb-2022), according to European Clinical Trials Database record.
- 03 Mar 2022 The trial has been completed in Hungary (trial end dat 11 Feb 2022), according to European Clinical Trials Database record.